CYTK News - Candlesense

Cytokinetics Names Jim Daly to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective Augus...

Corporate

3 days ago

Read more globenewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15, 2025 it granted stock options to purchase an aggregate ...

Compensation

4 days ago

Read more globenewswire

Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date

Are there any partnership or licensing opportunities that could be unlocked by a successful multi‑region approval of Aficamten? What is the expected impact on CYTK’s earnings per share and net loss if Aficamten launches as projected? How might the regulatory progress in multiple regions impact the valuation multiples applied to CYTK versus peers?

Earnings

16 days ago

Read more globenewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of...

Inducement

2 months ago

Read more globenewswire